CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Claire M. Lucas,L J Scott,Natasha Carmell,Alison K. Holcroft,Robert Kerrin Hills,Alan Kenneth Burnett,Richard E. Clark

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

2018

Claire M. Lucas
L J Scott
Natasha Carmell
Alison K. Holcroft
Robert Kerrin Hills
Alan Kenneth Burnett
Richard E. Clark

Key Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKT S473 phosphorylation is a predictor of survival, and diagnostic levels of AKT S473 could be a novel biomarker in AML.

Keywords:

Protein kinase B
Phosphorylation
Protein phosphatase 2
Cancer research
Biomarker (medicine)
Biology
Membrane protein
Nuclear protein
Chemistry
Karyotype
Proto-Oncogene Proteins c-akt

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations